Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results

Rhea-AI Summary

Accelerate Diagnostics (NASDAQ: AXDX) announced a conference call for August 5, 2021, at 4:30 p.m. ET to discuss its second quarter financial results for 2021. Interested parties can access the audio webcast online or by phone. The replay of the call will be available until August 26, 2021. The company specializes in in vitro diagnostics, focusing on antibiotic resistance and sepsis, through its Accelerate Pheno® system. This system enables faster antibiotic susceptibility results, which could optimize patient care significantly.

Positive

• Announcement of a scheduled conference call to discuss second quarter results, indicating transparency and communication with investors.
• Accelerate's technology offers results 1 to 2 days faster than existing methods, enhancing patient care and aligning with urgent healthcare needs.

Negative

• None.

TUCSON, Ariz., July 15, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time to review 2021 second quarter financial results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until November 5, 2021.

To listen by phone, dial +1.877.883.0383 and enter the conference ID: 5467079.  International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using the replay code 10157979 until August 26, 2021.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections. The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-schedules-call-to-review-2nd-quarter-2021-results-301334168.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is the conference call for Accelerate Diagnostics?

The conference call is scheduled for August 5, 2021, at 4:30 p.m. Eastern Time.

What will be discussed in the August 5, 2021 conference call?

The call will review the financial results for the second quarter of 2021.

How can I access the Accelerate Diagnostics conference call?

You can access the audio webcast online at ir.axdx.com or by phone at +1.877.883.0383.

What is the focus of Accelerate Diagnostics?

Accelerate Diagnostics specializes in in vitro diagnostics aimed at addressing antibiotic resistance and sepsis.

How does the Accelerate Pheno system improve antibiotic therapy?

It provides antibiotic susceptibility results in about 7 hours from positive blood cultures, 1 to 2 days faster than traditional methods.